Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,664
  • Shares Outstanding, K 40,514
  • Annual Sales, $ 20,920 K
  • Annual Income, $ -41,090 K
  • 60-Month Beta 1.95
  • Price/Sales 4.63
  • Price/Cash Flow N/A
  • Price/Book 2.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.40
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +43.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +89.23%
on 03/16/20
3.45 -28.70%
on 03/04/20
-0.40 (-13.99%)
since 03/03/20
3-Month
1.30 +89.23%
on 03/16/20
4.44 -44.59%
on 01/27/20
-0.97 (-28.28%)
since 01/03/20
52-Week
1.22 +101.23%
on 08/16/19
4.44 -44.59%
on 01/27/20
-0.25 (-9.23%)
since 04/03/19

Most Recent Stories

More News
What Makes Cidara Therapeutics (CDTX) a New Buy Stock

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CDTX : 2.46 (+2.93%)
Candidiasis Market to Surpass US$ 1,307.2 Million by 2026 | Key Companies are Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc

“t 2020 Global Industry Research report presents an in-depth analysis of the Candidiasis market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges,...

ALPMF : 15.9285 (+10.67%)
CDTX : 2.46 (+2.93%)
PBS.VN : 0.010 (unch)
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -44.83% and -83.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...

CDTX : 2.46 (+2.93%)
Cidara Therapeutics: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Cidara Therapeutics Inc. (CDTX) on Wednesday reported a loss of $14 million in its fourth quarter.

CDTX : 2.46 (+2.93%)
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for the...

CDTX : 2.46 (+2.93%)
Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CDTX : 2.46 (+2.93%)
Cidara Therapeutics to Present at Transplantation & Cellular Therapy (TCT) and Mycology 2020 Medical Conferences

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections, today announced that it...

CDTX : 2.46 (+2.93%)
Cidara Therapeutics Announces Closing of Rights Offering

Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, Cidara sold and issued an aggregate...

CDTX : 2.46 (+2.93%)
Cidara Therapeutics Announces Commencement of Rights Offering

Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara") today commenced the previously announced rights offering to raise gross proceeds of approximately $30.0 million (the "Rights Offering"). Under the terms...

CDTX : 2.46 (+2.93%)
New Strong Sell Stocks for January 16th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

CDTX : 2.46 (+2.93%)
CAPL : 9.35 (+12.24%)
CLB : 9.90 (+2.59%)
TS : 12.42 (+0.24%)
OCSL : 3.09 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade CDTX with:

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

2nd Resistance Point 2.56
1st Resistance Point 2.51
Last Price 2.46
1st Support Level 2.38
2nd Support Level 2.30

See More

52-Week High 4.44
Fibonacci 61.8% 3.21
Fibonacci 50% 2.83
Last Price 2.46
Fibonacci 38.2% 2.45
52-Week Low 1.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar